Life Sciences, Pharma & Healthcare

+ 22 other experts

The largest life sciences practice at a top-tier full-service firm in the Netherlands

.. with a practice that spans the entire spectrum of legal services relevant to the pharmaceutical and healthcare industry and to biotech companies.

We have strength and depth across this multifaceted sector, and advise on all relevant angles of legal life sciences work: ranging from M&A, financing transactions, IPOs (on Euronext Amsterdam, NASDAQ or other venues), corporate and governance, licensing transactions (often on a global scale), competition, regulatory and IP strategic advice through to litigation, compliance and investigations.

Our in-house capabilities give us a unique position from which to advise clients involved in life sciences matters which are by nature, often multidisciplinary. We are regularly retained for major transactions in the life sciences sector and our litigation department handles several of the largest healthcare and life sciences cases in the Netherlands, ranging from patent litigation to class actions pertaining to faulty medical devices and medicine.

Recent Matters

16 December 2024

De Brauw advises underwriters on NewAmsterdam Pharma's USD 479 million public offering of shares and pre-funded warrants

De Brauw advised the underwriters on the upsized USD 479 million public offering of shares and pre-funded warrants by NASDAQ listed NewAmsterdam Pharma Company N.V.
9 December 2024

QIAGEN N.V. to issue $500 million net share settled convertible bonds

QIAGEN N.V. has launched an issuance of USD 500 million senior unsecured net share settled convertible bonds. This type of bond differs from "regular" convertible bonds in that they may only partly - for the amount "in the money" under the embedded warrant - be converted into ordinary shares of the company. In the event of an exercise of their conversion right, holders of the convertible bonds receive a cash amount equivalent to the par value of the convertible bonds, plus a number of shares such that the sum of the cash amount and value of shares delivered is equivalent to the value of the shares underlying the convertible bonds. The 7-year convertible bonds with a denomination of USD 200,000 each carry a conversion price that represents a premium of 44% above the reference price of the shares.
2 August 2024

G Square agrees on the sale of the Duomed Group to Palex Medical

De Brauw advised G Square on the contemplated sale of its portfolio company, the Duomed Group to Palex Medical through execution of a put option agreement. The Duomed Group is a dynamic organization with a well-established reputation and is active in consultancy, sales, integration, training and technical support of medical technology and devices for hospitals and medical practices. The Duomed Group is active in Denmark, Sweden, The Netherlands, Belgium, Luxembourg, France, Switzerland, the UK, Serbia and Slovenia. The envisaged transaction would form a truly pan-European platform, providing medical technology equipment and solutions across Northern, Western, and Southern Europe
Landscape debrauw paper blackstone duo high res 3

We cover a broad spectrum of Life Sciences work for pharmaceutical companies, biotech firms and medical supply companies.

On behalf of our strong client base in the food and drink industry (Unilever, PepsiCo, Danone, JDE and P&G to name but a few), we have a leading role in developments relating to food claims and the actions taken by the European Food Safety Authority (EFSA).

We are the patent litigation firm of choice for many multinationals wishing to coordinate their patent strategy throughout Europe. Our Patent Law practice members combine their strong foundation in patent and procedural law with their extensive knowledge of the economics of, and the mechanisms, in this sector.

Learn More about our patents practice

A strong Dutch full service firm with the patent department also having a focus on Life Sciences... unique in combining legal and technical thinking when developing strategies and arguments. This team is unique in their extraordinary ability to learn the subject matter in a very short time, applying it in court and turn it into victory... They are a pleasure to work with both on a professional and a personal level.

Legal 500, 2021

Insights

17 December 2024

FRAND developments in the Unified Patent Court: where do we stand?

On 22 November 2024, in a case between Panasonic and OPPO, the Mannheim Local Division (LD) of the Unified Patent Court (UPC) handed down the first ever full-fledged substantive decision on the licensing of standard essential patents (SEPs) on Fair, Reasonable and Non-Discriminatory (FRAND) terms. The UPC had already dealt with FRAND cases in the context of procedural orders. Below we provide a brief overview of these developments, which are relevant to both SEP holders and implementers.
29 February 2024

EU plans revamp of FDI rules: what you need to know

The European Commission unveiled a proposal on 24 January 2024 aimed at revamping the current European framework for screening foreign direct investments (FDI), signalling new requirements for member states. The initiative is part of a package of five measures seeking to strengthen the EU's economic security at a time of growing geopolitical tensions and profound technological shifts. The Proposed FDI Screening Regulation is in a more advanced stage than the remaining four initiatives. These include white papers – on export controls, outbound investment and enhancing R&D support for technologies with dual-use potential – and a proposal for a Council recommendation on enhancing research security. Businesses and investors entering or expanding in the EU market must take heed of the rapidly changing regulatory environment, especially regarding investments in critical infrastructure, sensitive technology and other areas that are important to the EU's economic security.
26 October 2023

Anne Marie Verschuur appointed as Member of Honour by AIPPI

Anne Marie Verschuur has been appointed as Member of Honour of the International Association for the Protection of Intellectual Property (AIPPI) during its World Congress in Istanbul. She served for many years in the international board of AIPPI, including as Reporter General. Anne Marie was furthermore recently appointed as President of the Dutch group of AIPPI (the Dutch Association for Intellectual Property) as per the end of this year.

Team

Bertrand ter Woort

Senior Associate

Bernard Spoor

Retired partner | Brauwerij supervisor